News & Publications

Press Releases

April 22, 2025
FDA grants Breakthrough Therapy Designation for BrainChild Bio’s B7-H3 CAR T-cell therapy for incurable pediatric brain tumors
January 7, 2025
BrainChild Bio, Inc. to clinically advance BCB-276, an autologous B7-H3 targeting CAR T-cell therapy for incurable pediatric brain tumors
December 5, 2023
Seattle Children’s launches BrainChild Bio to accelerate CAR T-cell therapies for children with brain tumors
MORE

Publications

January 7, 2025
Intracerebroventricular B7-H3-targeting CAR T cells for diffuse intrinsic pontine glioma: a phase 1 trial
Nature Medicine

In The News

September 8, 2026
BrainChild Bio gets $116M for pivotal trial of pediatric brain tumor CAR-T
Endpoints News
September 8, 2026
With $116M in Series A Financing, BrainChild Bio Targets CNS Tumors, Starting with One in Children’s Brainstems
Genetic Engineering News
December 5, 2023
A CAR-T therapy invented at Seattle Children’s was never approved for kids. Now the hospital is launching its own pediatric CAR-T startup
Endpoints News
December 5, 2023
Seattle Children’s spins out BrainChild Bio, a startup developing therapies for incurable brain cancers
GeekWire

For press inquiries, please contact:

Barbara Yates
781-258-6153
barbara@theyatesnetwork.com